Trial Profile
Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Evaluate Safety and Efficacy of H56:IC31 in Reducing the Rate of TB Disease Recurrence in HIV Negative Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs H56IC (Primary)
- Indications Pulmonary tuberculosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Aeras
- 06 Mar 2024 Results assessing if H56:IC31 can reduce the risk of recurrent TB, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 25 Oct 2023 Planned End Date changed from 31 Dec 2024 to 30 Mar 2024.
- 01 Feb 2023 Status changed from recruiting to active, no longer recruiting.